Description

Parkizol (pramipexole dihydrochloride) tablets 1 mg. №30

Ingredients

Active ingredient: Pramipexole dihydrochloride
Other ingredients: lactose monohydrate, maize starch, colloidal anhydrous silica, magnesium stearate.

Dosage

Recommended dosage: The usual starting dose is 0.125 mg taken once daily 2-3 hours before bedtime. The dose may be gradually increased every 4-7 days.

Indications

Parkizol tablets are indicated for the treatment of:
– Parkinson’s disease
– Restless legs syndrome (RLS)

Contraindications

Do not use Parkizol tablets if:
– You are allergic to pramipexole or any other ingredients in the tablets.
– You have severe kidney problems.

Directions

– Swallow the tablet whole with a glass of water.
– Do not crush, chew, or break the tablet.
– Follow the dosage instructions provided by your healthcare provider.

Scientific Evidence

Parkizol (pramipexole dihydrochloride) has shown significant efficacy in the treatment of Parkinson’s disease and restless legs syndrome. Studies have demonstrated its ability to improve motor symptoms in Parkinson’s disease and reduce the symptoms of RLS, leading to improved quality of life for patients. Research published in the Journal of Neurology supports the use of pramipexole for the management of these conditions.

Additional Information

– It is important to follow the prescribed dosage and not exceed the recommended amount to avoid potential side effects.
– Inform your healthcare provider about any other medications you are taking to prevent interactions with Parkizol tablets.

Pharmacological Effects: Pramipexole is a dopamine agonist that works by stimulating dopamine receptors in the brain. This action helps to improve motor function in Parkinson’s disease and alleviate the symptoms of restless legs syndrome.

Clinical Trials: Clinical trials have shown that pramipexole is effective in reducing the symptoms of Parkinson’s disease, such as tremors, stiffness, and slowness of movement. In a study published in Movement Disorders, pramipexole was found to be well-tolerated and significantly improved motor function in patients with early Parkinson’s disease.